Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.84 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.84 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.84 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.84 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.84 |
| ▸ | HTR2B | P41595 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramosetron SCHEMBL9048395 | 1.00 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL2021739 | 1.00 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL13531398 | 1.00 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL29395241 | 1.00 | HTR3A (0.84) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL3175461 | 0.99 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL447023 | 0.99 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL30318895 | 0.99 | HTR3A (0.83) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9052272 | 0.94 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL9048659 | 0.94 | HTR3A (0.75) | HTR3AADRA2AADRA2BHTR3EHTR3B | |
| Ramosetron SCHEMBL1649718 | 0.92 | HTR3A (1.00) | HTR3AADRA2AADRA2BHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11300 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260130929-A1 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-3615024-B1 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | ALTO NEUROSCIENCE INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | claimed |
| US-6235745-B1 | ADMINISTERING WITH LAXATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-22 | — | — | US | claimed |
| WO-2001010423-A2 | USE OF 5-HT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATIONS OF THE RESPIRATORY TRACT | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000048597-A1 | SYSTEMIC USE OF 5-HT3 RECEPTOR ANTAGONISTS AGAINST RHEUMATIC INFLAMMATORY PROCESSES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000048581-A2 | USE OF 5-HT3 RECEPTOR ANTAGONISTS FOR TREATING MUSCULOESKELETAL DISEASES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1021174-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0975327-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-02-02 | — | — | EP | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| WO-1998047481-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | claimed |